Vitamin K prophylaxis in neonates: comparing two different oral regimens

J Perinatol. 2024 Oct;44(10):1491-1495. doi: 10.1038/s41372-024-01981-9. Epub 2024 Apr 27.

Abstract

Objective: This prospective study compared PIVKA-II and PT-INR levels in infants who received two vitamin K (VK) prophylactic regimens.

Methods: A single institution administered 119 healthy newborns 2 mg of VK syrup. Infants were assigned to a 3-time regimen (n = 56) with VK at birth, five days (5D), and 1-month-old (1 M), or a 13-time regimen (n = 63) with VK at birth, 5D, and then weekly for 11 weeks.

Results: The 13-time regimen significantly lowered PIVKA-II and reduced PT-INR at 1 M in both breastfed (PIVKA-II: 18-16 mAU/mL, p = 0.02; PT-INR: 1.37-1.13, p < 0.01) and formula-fed infants (PIVKA-II: 18-15 mAU/mL, p = 0.01; PT-INR: 1.54-1.24, p < 0.01), compared to baseline measurements taken at 5D. The 3-time regimen did not significantly alter PIVKA-II levels and only improved PT-INR (2.00-1.50, p < 0.01) in formula-fed infants.

Conclusion: The 13-time VK regimen significantly enhanced coagulation profiles more effectively than the 3-time regimen.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Biomarkers / blood
  • Breast Feeding
  • Drug Administration Schedule
  • Female
  • Humans
  • Infant, Newborn
  • International Normalized Ratio
  • Male
  • Prospective Studies
  • Protein Precursors
  • Prothrombin* / analysis
  • Vitamin K Deficiency Bleeding / prevention & control
  • Vitamin K* / administration & dosage

Substances

  • Vitamin K
  • Prothrombin
  • acarboxyprothrombin
  • Biomarkers
  • Protein Precursors